ArticleThe Journal of infection2014
Interferon lambda 1-3 expression in infants hospitalized for RSV or HRV associated bronchiolitis.
Article in The Journal of infection, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Burden and Characteristics of Respiratory Syncytial Virus-Associated Bronchiolitis in Hospitalized Infants in Italy: A Systematic Review.Immunity, inflammation and disease · 2026Pooled it
- The Human Immune Response to Respiratory Syncytial Virus Infection.Clinical microbiology reviews · 2017Pooled it
- Respiratory syncytial viral load drives ciliated cell dedifferentiation and suppresses antiviral immunity.Science advances · 2026Article
- Interferon-λ3 rs12979860 polymorphism and early-life RSV-bronchiolitis are associated with persistent asthma in male children: a 4-year prospective follow-up study.Pediatric research · 2026Article
- IFN-λ4 Exhibits Differential Induction and Antiviral Activity in RSV and HMPV Infections.Viruses · 2026Article
- Differential antiviral effects and immune responses in nasal and airway organoid during RSV infection: implications for interferon therapy.Frontiers in immunology · 2026Article
- B-Raf kinase blockade protects airway epithelial cells against respiratory syncytial virus infection and modulates interferon responses.ERJ open research · 2025Article
- Age Matters: Key Contributors to Interferon Toxicity in Infants During Influenza Virus Infection.Viruses · 2025Review
- Immune Response to Respiratory Viral Infections.International journal of molecular sciences · 2024Review
- Review
- Review
- Interferons-Implications in the Immune Response to Respiratory Viruses.Microorganisms · 2023Review
- NRF2 Antioxidant Response and Interferon-Stimulated Genes Are Differentially Expressed in Respiratory-Syncytial-Virus- and Rhinovirus-Infected Hospitalized Children.Pathogens (Basel, Switzerland) · 2023Article
- Current Landscape of IFN-λ: Induction, Inhibition, and Potential Clinical Applications to Treat Respiratory Viral Infections.ImmunoHorizons · 2023Article
- Emerging role for interferons in respiratory viral infections and childhood asthma.Frontiers in immunology · 2023Article
- Type III Interferons, Viral Loads, Age, and Disease Severity in Young Children With Respiratory Syncytial Virus Infection.The Journal of infectious diseases · 2022Article
- Review
- Lack of Type I Interferon Signaling Ameliorates Respiratory Syncytial Virus-Induced Lung Inflammation and Restores Antioxidant Defenses.Antioxidants (Basel, Switzerland) · 2021Article
- Immunopathology of RSV: An Updated Review.Viruses · 2021Review
- Reversible disruption of XPO1-mediated nuclear export inhibits respiratory syncytial virus (RSV) replication.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe airway expression of type III interferons (IFNs) was evaluated in infants hospitalized for respiratory syncytial virus (RSV) or rhinovirus (HRV) bronchiolitis. As an additional objective we sought to determine whether a different expression of IFN lambda 1-3 was associated with different harboring viruses, the clinical course of bronchiolitis or with the levels of well established IFN stimulated genes (ISGs), such as mixovirus resistance A (MxA) and ISG56.
methodsThe analysis was undertaken in 118 infants with RSV or HRV bronchiolitis. Nasopharyngeal washes were collected for virological studies and molecular analysis of type III IFN responses.
resultsRSV elicited higher levels of IFN lambda subtypes when compared with HRV. A similar expression of type III IFN was found in RSVA or RSVB infected infants and in those infected with HRVA or HRVC viruses. Results also indicate that IFN lambda 1 and IFN lambda 2-3 levels were correlated with each other and with MxA and ISG56-mRNAs. In addition, a positive correlation exists between the IFN lambda1 levels and the clinical score index during RSV infection. In particular, higher IFN lambda 1 levels are associated to an increase of respiratory rate.
conclusionsThese findings show that differences in the IFN lambda 1-3 levels in infants with RSV or HRV infections are present and that the expression of IFN lambda 1 correlates with the severity of RSV bronchiolitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.